These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25175981)

  • 1. Patients with type 2 diabetes mellitus failing on oral agents and starting once daily insulin regimen; a small randomized study investigating effects of adding vildagliptin.
    de Ranitz-Greven WL; Beulens JW; Hoeks LB; Belle-van Meerkerk G; Biesma DH; de Valk HW
    BMC Res Notes; 2014 Aug; 7():579. PubMed ID: 25175981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment.
    Kanazawa I; Tanaka KI; Notsu M; Tanaka S; Kiyohara N; Koike S; Yamane Y; Tada Y; Sasaki M; Yamauchi M; Sugimoto T
    Diabetes Res Clin Pract; 2017 Jan; 123():9-17. PubMed ID: 27914297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus.
    Ning G; Wang W; Li L; Ma J; Lv X; Yang M; Wang W; Woloschak M; Lukashevich V; Kothny W
    J Diabetes; 2016 May; 8(3):345-53. PubMed ID: 25929739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes.
    He YL; Valencia J; Zhang Y; Schwartz SL; Ligueros-Saylan M; Foley J; Dole WP
    Br J Clin Pharmacol; 2010 Jul; 70(1):34-42. PubMed ID: 20642545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment.
    Lukashevich V; Schweizer A; Foley JE; Dickinson S; Groop PH; Kothny W
    Vasc Health Risk Manag; 2013; 9():21-8. PubMed ID: 23378769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update: vildagliptin for the treatment of Type 2 diabetes.
    Garber AJ; Sharma MD
    Expert Opin Investig Drugs; 2008 Jan; 17(1):105-13. PubMed ID: 18095923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
    He YL
    Clin Pharmacokinet; 2012 Mar; 51(3):147-62. PubMed ID: 22339447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and tolerability of second-line therapy with vildagliptin versus other oral agents in type 2 diabetes (EDGE): post-hoc subanalysis of the Belgian data.
    Hoste J; Daci E; Mathieu C
    Acta Clin Belg; 2014 Jun; 69(3):171-6. PubMed ID: 24820924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
    Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
    Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).
    Sakamoto M; Nishimura R; Irako T; Tsujino D; Ando K; Utsunomiya K
    Cardiovasc Diabetol; 2012 Aug; 11():92. PubMed ID: 22867630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes.
    Farngren J; Persson M; Schweizer A; Foley JE; Ahrén B
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3799-806. PubMed ID: 22855332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin.
    Forst T; Bramlage P
    Expert Opin Pharmacother; 2014 Jun; 15(9):1299-313. PubMed ID: 24837407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of vildagliptin on glucose and insulin concentrations during a 24-hour period in type 2 diabetes patients with different ranges of baseline hemoglobin A1c levels.
    González-Ortiz M; Sánchez-Peña MJ; González-Ortiz LJ; Robles-Cervantes JA; García-Ortega YE; Gómez-Gaitán EA; Pérez-Rubio KG; Martínez-Abundis E
    Diabetes Technol Ther; 2013 Jul; 15(7):564-8. PubMed ID: 23617250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes.
    Dalla Man C; Bock G; Giesler PD; Serra DB; Ligueros Saylan M; Foley JE; Camilleri M; Toffolo G; Cobelli C; Rizza RA; Vella A
    Diabetes Care; 2009 Jan; 32(1):14-8. PubMed ID: 18931099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations.
    Marfella R; Barbieri M; Grella R; Rizzo MR; Nicoletti GF; Paolisso G
    J Diabetes Complications; 2010; 24(2):79-83. PubMed ID: 19261490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes.
    Fonseca V; Schweizer A; Albrecht D; Baron MA; Chang I; Dejager S
    Diabetologia; 2007 Jun; 50(6):1148-55. PubMed ID: 17387446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of vildagliptin on hepatic steatosis.
    Macauley M; Hollingsworth KG; Smith FE; Thelwall PE; Al-Mrabeh A; Schweizer A; Foley JE; Taylor R
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1578-85. PubMed ID: 25664602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes.
    Serra D; He YL; Bullock J; Riviere GJ; Balez S; Schwartz S; Wang Y; Ligueros-Saylan M; Jarugula V; Dole WP
    Int J Clin Pharmacol Ther; 2008 Jul; 46(7):349-64. PubMed ID: 18793589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl peptidase-4 inhibitor (vildagliptin) improves glycemic control after meal tolerance test by suppressing glucagon release.
    Okamoto A; Yokokawa H; Sanada H
    Drugs R D; 2014 Dec; 14(4):227-32. PubMed ID: 25204760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vildagliptin: a review of its use in type 2 diabetes mellitus.
    Keating GM
    Drugs; 2014 Apr; 74(5):587-610. PubMed ID: 24638989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.